Rosenberg, Holt, Zinser and Ganeles P.A. Among First Periodontists in Nation To Use New FDA-Approved Treatment

Apr 18, 2001, 01:00 ET from Rosenberg, Holt, Zinser and Ganeles P.A.

    BOCA RATON, Fla., April 18 /PRNewswire/ -- The Palm Beach County-based
 dental practice of Rosenberg, Holt, Zinser and Ganeles P.A. announced today
 it's among the first to offer patients a revolutionary treatment in the fight
 against periodontal disease, a condition affecting more than 50 million
 Americans.
     Founding partner Dr. Marvin M. Rosenberg said the practice,
 internationally known for developing and implementing leading technology in
 its field, is using the new pharmaceutical product Arestin(TM) for the
 adjunctive treatment of adult periodontitis -- a bacterial infection of the
 gum and bone tissue. Arestin, which is distributed by OraPharma Inc., was
 approved by the FDA in February 2001.
     "We think it's a perfect fit with our efforts to stay at the forefront of
 the procedures and technologies of our profession," said Rosenberg.  "Instead
 of prescribing an oral antibiotic taken several times daily that disperses
 throughout the body, we're using Arestin.  It's an antibiotic encapsulated in
 unique dissolving microspheres which are painlessly inserted directly into the
 infected area between the teeth and gum."
     Arestin uses patented microsphere technology to deliver the antibiotic
 minocycline beneath the gum, directly into the infected periodontal pocket
 after deep cleaning of the teeth and gums with a procedure known as scaling
 and root planing.  Arestin is highly bioadhesive and does not require
 retention dressings and will not leak or fall out.  In addition, it does not
 require mixing or refrigeration in the dentist's office.  Arestin is
 completely reabsorbed, which means patients don't have to return to the
 dentist for product removal and can resume routine oral hygiene 12 hours after
 administration.
     "We are pleased that high quality firms like Rosenberg, Holt, Zinser and
 Ganeles P.A. are choosing to use Arestin," said Joe Zack, vice president of
 sales and marketing at OraPharma.
     Dr. Robert Holt, a partner with the practice, will lead conferences in the
 area on the proper use of Arestin.  Teaching breakthrough techniques is not
 new to Holt.  He is a visiting assistant professor at Nova Southeastern
 University College of Dental Medicine in Fort Lauderdale, Fla. and co-author
 of the widely published textbook, "Periodontal and Prosthetic Management of
 the Advanced Case."
     For 40 years Rosenberg, Holt, Zinser and Ganeles P.A. has been on the
 leading edge of periodontal practice.  Its work in the areas of periodontics
 and implantology is world-renowned and its periodontists are consulted
 internationally for their knowledge and techniques.  Partners in the firm
 include Marvin M. Rosenberg, D.D.S. F.A.C.D.; Robert L. Holt, D.M.D., Ph.D.,
 F.A.C.D.; Phillip J. Zinser, D.D.S.; Jeffrey Ganeles, D.M.D., F.A.C.D. and
 associates Sherrie L. Crossen, D.D.S., M.S.D and Peter R. Then, D.M.D.,
 Dr.med.dent.  The practice conducts more than 4,000 surgical procedures
 annually at its offices in Boca Raton and West Palm Beach, Florida.  Its
 website at www.perio-implant.com delivers a wealth of information on
 periodontal disease.
     Contact: Joel Staley of The TransMedia Group, 561-750-9800, ext. 21, or
 jstaley@transmediagroup.com
 
 

SOURCE Rosenberg, Holt, Zinser and Ganeles P.A.
    BOCA RATON, Fla., April 18 /PRNewswire/ -- The Palm Beach County-based
 dental practice of Rosenberg, Holt, Zinser and Ganeles P.A. announced today
 it's among the first to offer patients a revolutionary treatment in the fight
 against periodontal disease, a condition affecting more than 50 million
 Americans.
     Founding partner Dr. Marvin M. Rosenberg said the practice,
 internationally known for developing and implementing leading technology in
 its field, is using the new pharmaceutical product Arestin(TM) for the
 adjunctive treatment of adult periodontitis -- a bacterial infection of the
 gum and bone tissue. Arestin, which is distributed by OraPharma Inc., was
 approved by the FDA in February 2001.
     "We think it's a perfect fit with our efforts to stay at the forefront of
 the procedures and technologies of our profession," said Rosenberg.  "Instead
 of prescribing an oral antibiotic taken several times daily that disperses
 throughout the body, we're using Arestin.  It's an antibiotic encapsulated in
 unique dissolving microspheres which are painlessly inserted directly into the
 infected area between the teeth and gum."
     Arestin uses patented microsphere technology to deliver the antibiotic
 minocycline beneath the gum, directly into the infected periodontal pocket
 after deep cleaning of the teeth and gums with a procedure known as scaling
 and root planing.  Arestin is highly bioadhesive and does not require
 retention dressings and will not leak or fall out.  In addition, it does not
 require mixing or refrigeration in the dentist's office.  Arestin is
 completely reabsorbed, which means patients don't have to return to the
 dentist for product removal and can resume routine oral hygiene 12 hours after
 administration.
     "We are pleased that high quality firms like Rosenberg, Holt, Zinser and
 Ganeles P.A. are choosing to use Arestin," said Joe Zack, vice president of
 sales and marketing at OraPharma.
     Dr. Robert Holt, a partner with the practice, will lead conferences in the
 area on the proper use of Arestin.  Teaching breakthrough techniques is not
 new to Holt.  He is a visiting assistant professor at Nova Southeastern
 University College of Dental Medicine in Fort Lauderdale, Fla. and co-author
 of the widely published textbook, "Periodontal and Prosthetic Management of
 the Advanced Case."
     For 40 years Rosenberg, Holt, Zinser and Ganeles P.A. has been on the
 leading edge of periodontal practice.  Its work in the areas of periodontics
 and implantology is world-renowned and its periodontists are consulted
 internationally for their knowledge and techniques.  Partners in the firm
 include Marvin M. Rosenberg, D.D.S. F.A.C.D.; Robert L. Holt, D.M.D., Ph.D.,
 F.A.C.D.; Phillip J. Zinser, D.D.S.; Jeffrey Ganeles, D.M.D., F.A.C.D. and
 associates Sherrie L. Crossen, D.D.S., M.S.D and Peter R. Then, D.M.D.,
 Dr.med.dent.  The practice conducts more than 4,000 surgical procedures
 annually at its offices in Boca Raton and West Palm Beach, Florida.  Its
 website at www.perio-implant.com delivers a wealth of information on
 periodontal disease.
     Contact: Joel Staley of The TransMedia Group, 561-750-9800, ext. 21, or
 jstaley@transmediagroup.com
 
 SOURCE  Rosenberg, Holt, Zinser and Ganeles P.A.